XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, has joined the Personalized Medicine Coalition, (PMC) an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine, defined as the application of genomic and molecular data to better target the delivery of healthcare by determining a person's predisposition to a particular disease or condition.
“The current regulatory and reimbursement environment can be slow to recognize the uniqueness of diagnostics that support personalized medicine. It is XIFIN’s goal to work with the PMC to help evolve reimbursement policies and practices that are supportive of personalized medicine and better reflect their value.”
XIFIN’s service model includes partnership and advocacy on behalf of both early stage and leading laboratories and molecular diagnostic companies involved in technologies that advance personalized medicine. The company actively participates in the development of key open standards within the industry including Health Level 7 (HL7), the Workgroup for Electronic Data Interchange (WEDI) and the HIPAA 5010 format. As an advocate for practices and policies that affect diagnostic services, XIFIN is a long standing member of various industry organizations like the American Clinical Laboratories Association (ACLA) and California Clinical Laboratory Association (CCLA).
“The PMC allows a variety of stakeholders to work together to understand the challenges and issues impacting the advancement of personalized medicine,” said Lale White, CEO of XIFIN. “The current regulatory and reimbursement environment can be slow to recognize the uniqueness of diagnostics that support personalized medicine. It is XIFIN’s goal to work with the PMC to help evolve reimbursement policies and practices that are supportive of personalized medicine and better reflect their value.”
The coalition is comprised of academic, industrial, patient, provider and payer organizations promoting the understanding and adoption of personalized medicine through a number of initiatives. Since its launch in 2004, the coalition has provided leadership and a forum for education and advocacy for the public, policymakers, government officials and private sector healthcare leaders to further the public interest in personalized medicine.
AI and predictive medicine: Recent advances